Last reviewed · How we verify
Pregablin
At a glance
| Generic name | Pregablin |
|---|---|
| Sponsor | National Cancer Institute, Egypt |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Preoperative Pregabalin vs Gabapentin in Elderly Undergoing Surgry,Controlled Trial (NA)
- Improving Pain Management and Long Term Outcomes Following High Energy Orthopedic Trauma (Pain Study) (PHASE3)
- Comparison of Duloxetine Versus Pregabalin (PHASE2)
- IPACK Nerve Block for Total Knee Arthroplasty (PHASE4)
- Clinical Trial to Evaluate the Efficacy and Safety of 'GLA5PR GLARS-NF1 Tab.' in Peripheral Neuropathic Pain (PHASE3)
- Pregablin for Anxiety-comorbidity in Patients With Schizophrenia (PHASE4)
- Development of a Personalised Care Plan Designed to Reduce Chronic Post-Operative Pain Following Breast Surgery (NA)
- Pregabalin Compared to Gabapentin for Pain Control in Lumbar Disc Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pregablin CI brief — competitive landscape report
- Pregablin updates RSS · CI watch RSS
- National Cancer Institute, Egypt portfolio CI